Navigation Links
Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California.   

The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond.

Specifically, the Company will discuss the recent very productive Type C meeting that was held with the FDA on elagolix for endometriosis, one of the outcomes of which was the decision to file a Special Protocol Assessment (SPA) with the FDA. The expected NDA filing of elagolix for the treatment of endometriosis is in 2015.

Additionally, the presentation will cover the Company's VMAT2 program for movement disorders, including the status of the current Phase II study assessing the impact of NBI-98854 in patients with tardive dyskinesia. This study, which began in the fall of 2011, has recently completed enrollment and will report top-line data in the first quarter of 2012.  The Company also recently received a notification of allowable claims for its NBI-98854 European Patent Application from the European Patent Office, and has begun planning for larger Phase IIb trials, to be launched in mid-2012, for up to three months of continuous treatment with NBI-98854.

 

The live presentation takes place on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  A copy of the presentation materials will be filed with the Securities and Exchange Commission on or before Monday, January 9, 2012.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
6. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
7. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
8. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
10. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
11. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , USA, March 29, 2017 Stryker announced ... Cares by People magazine, in partnership with Great Place ... companies on the list. This list highlights the top ... succeeded in business while also demonstrating respect, compassion and ... To determine the companies on the ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 FinancialBuzz.com ... Data published in ... medical cannabis market will reach a value of USD 55.8 billion by ... the United States and a more open approach ... Arkansas , Florida , North Dakota ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Outlook: 2016-2022" report to their offering. ... The global patient safety and risk ... end-user, and geography. Patient safety has become a ... field has developed significantly in the last decade and is currently ...
Breaking Medicine Technology:
(Date:3/29/2017)... Md., and MINNETONKA, Minn. (PRWEB) , ... March ... ... the development of medical office buildings (MOBs) and other outpatient facilities, and who ... project to look exclusively at those questions, Revista and Healthcare Real Estate Insights ...
(Date:3/29/2017)... Norwalk, CT (PRWEB) , ... March 29, 2017 , ... ... Valuing —on Thursday, April 20, 2017, at 1:00 PM ET. A recording of the ... of the Interactive Webinar Series. , Home health and hospice companies are still popular ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... ... ... the eastern suburbs and South Hills of Pittsburgh now have easier access ... western Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes ...
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):